Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate

R&D Systems, part of Bio-Techne | Catalog # ATM193

Fc Chimera
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
ATM193-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Learn more about FluorokinesTM Fluorescent-Labeled Proteins

Source

NS0

Accession #

Q6PE46

Structure / Form

Disulfide-linked homodimer, labeled with Atto 647N via amines


Excitation Wavelength: 647 nm
Emission Wavelength: 667 nm

Conjugate

ATTO 647N (Excitation= 647 nm, Emission= 667 nm)

Applications

Bioactivity

View all BCMA/TNFRSF17 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human BCMA/TNFRSF17 protein
Human BCMA/TNFRSF17
(Met1-Ala54)
Accession # Q6PE46		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met1

Predicted Molecular Mass

32 kDa (monomer)

SDS-PAGE

35-45 kDa, under reducing conditions

Activity

Measured by flow cytometry for its ability to bind anti-Human BCMA Monoclonal Antibody conjugated fluorescent beads.

Scientific Data Images for Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate

Detection of Human BCMA Antibody with Recombinant Human BCMA/TNFRSF17 Fc Chimera Atto 647N Protein by Flow Cytometry.

Fluorescent beads conjugated to anti-Human BCMA Monoclonal Antibody were stained with (A) Recombinant Human BCMA/TNFRSF17 Fc Chimera Atto 647N Protein (Catalog # ATM193) or (B) unstained.
Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate SDS-PAGE

Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate SDS-PAGE.

2 μg/lane of Recombinant BCMA/TNFRSF17 Fc Chimera Atto 647N (ATM193) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 35-45 kDa and 70-90 kDa, respectively.

Formulation, Preparation and Storage

ATM193
Formulation Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: BCMA/TNFRSF17

BCMA, B cell maturation antigen, also known as Tumor Necrosis Factor Receptor Superfamily member 17 (gene name TNSFR17), is a member of the TNFR superfamily, due to the presence of its TNFR motif (1). BCMA is a type III membrane protein containing one extracellular cysteine rich domain, a transmembrane domain, and an intracellular domain. Within the TNFRSF, it shares the highest homology with TACI. BCMA and TACI have both been shown to bind to APRIL and BAFF, members of the TNF ligand superfamily (2, 3). This binding to APRIL and BAFF has been shown to stimulate IgM production in peripheral B cells and increase the survival of cultured B cells (3, 4). This data suggests that BCMA may play an important role in B cell development, function, and regulation (5). BCMA expression has been found in immune organs and mature B cell lines (5). Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment (6). Within the ECD, human and mouse BCMA shares 62% amino acid identity. The expression of BCMA has also been linked to various cancers, autoimmune disorders, and infectious diseases (7). Proteolytic shedding of the BCMA extracellular domain generats soluble BCMA (sBCMA) via direct cleavage by gamma -secretase, and elevated sBCMA levels in serum may correlate with disease activity (8). More recently, BCMA has been indicated as a possible biomarker in various human immunological disease, and as a potential therapeutic target for multiple myeloma (MM) (9-11).

References

  1. Hatzoglou, A. et al. (2000). J Immunol. 165:1322.
  2. Schiemann, B. et al. (2001). Science. 293:2111.
  3. Marsters, S.A. et al. (2000) Curr. Biol. 10:785.
  4. Huang, H. et al. (2013). PNAS. 110:10928.
  5. Laâbi, Y. et al. (1994). Nucleic Acids Res. 22:1147.
  6. Gras, M. et al. (1995) Int. Immunol. 7:1093.
  7. Coquery, C.M. et al. (2012) Crit Rev Immunol. 32:287.
  8. Laurent, S.A. et al. (2015) Nat Commun. 6:7333.
  9. Thaler, F.S. et al. (2017) Neuro Oncol. 19:1618.
  10. Seckinger, A. et al. (2017) Cancer Cell. 31:396.
  11. Lee, L. et al. (2018) Blood. 131:746.

Long Name

B Cell Maturation Factor

Alternate Names

CD269, TNFRSF13A, TNFRSF17

Entrez Gene IDs

608 (Human); 21935 (Mouse); 287034 (Rat); 102145399 (Cynomolgus Monkey)

Gene Symbol

TNFRSF17

UniProt

Q6PE46

Additional BCMA/TNFRSF17 Products

Product Documents for Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human BCMA/TNFRSF17 Protein, Atto 647N Conjugate

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.